Launch of TASECTAN® AF in Denmark
Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market, after Noventure granted Pharmaforce exclusive distribution right for Tasectan® AF in the Nordic markets last April.
Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children.